Abstract:
Introduction: With healthcare-associated infections (HAIs) and antimicrobial resistance posing a global challenge, Mexico joins international efforts with the firm conviction that by standardizing, implementing, and monitoring compliance with criteria proven to prevent HAIs, we can achieve significant progress. 1 It is urgently necessary to change how antibiotics are prescribed and used. Even with the development of new medications, if current practices are not modified, antibiotic resistance will continue to pose a serious threat. 2 Objective: Understanding bacterial resistance and susceptibility profiles for the rational use of antimicrobials.
Methodology: Our data source is the information contained in the INOSO institutional database, where we captured all healthcare-associated infections. Analysis of the bacteriological profile, as well as their susceptibility and resistance, was performed for 2025.
Results: The main hospital-acquired bacteria during 2025 was S. aureus, followed by A. baumanni, primarily found in ventilator-associated pneumonia (VAP), followed by S. epidermidis, E. coli, K. pneumoniae, and P. aeruginosa, which grew in the main healthcare-associated infections (HAIs) of the different types of infection during 2025. S. aureus showed resistance to penicillins, azithromycin, and gentamicin in 50-80% of cases, and sensitivity to levofloxacin, moxifloxacin, ceftriaxone, linezolid, rifampicin, TMP-SMZ, and vancomycin in 60-74% of cases. A. baumanni showed resistance in 50-84% of cases to hospital-used antibiotics, as well as broad-spectrum antibiotics. For S. epidermidis, resistance is increasing to various antibiotic groups, with sensitivity to rifampicin, linezolid, and vancomycin. E. coli exhibits over 75% resistance to third-generation cephalosporins, and sensitivity to carbapenems is over 80%. Amikacin should be considered, with intermediate resistance at 54%. P. aeruginosa shows significant resistance to cephalosporins and imipenem (over 60%), making options such as meropenem, levofloxacin, amikacin, and norfloxacin viable.
Conclusion: Our commitment is to reduce complications in patients with healthcare-associated infections (HAIs), costs, and hospital overstays, and to raise awareness about the rational use of antimicrobials. The goals are: to ensure that medical notes reference our hospital's local antibiotic guidelines; to implement antibiotic restraint with the support of infectious disease specialists; to present evidence of progress to the Antimicrobial Subcommittee and CODECIAAS; and to analyze the AWaRe system and disseminate information in general sessions and to attending physicians. We also aim to maintain and progressively decrease resistance rates and maintain susceptibility to microorganisms for two years
Biography:
Epidemiologist, IMSS General Hospital of Zone #1, Medical Subdirector of the Civil Hospital of the Ministry of Health, Specialist Epidemiologist, Diploma in Hospital Certification, Diploma in Hospital Administration, Diploma in Hospital Management, Speaker at National and International Congresses, Attendee at Les Nouvelles transitions Epidemiologiques, July 2024, Limoges, France, Author of four antibiotic guides for General Hospital of Zone #1 Tepic, Nayarit, INTERNATIONAL SPEAKER at the congress: 8TH EDITION OF WORLD CONGRESS ON INFECTIOUS DISEASES CONFERENCE PROGRAM JUNE 09-11, 2025 ROME, ITALY
